Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.

@article{Prez2008SafetyIA,
  title={Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.},
  author={Gonzalo P{\'e}rez and Eduardo Lazcano-Ponce and Mauricio Hern{\'a}ndez-{\'A}vila and Patricia J. Garcia and Nubia Mu{\~n}oz and Luisa L. Villa and Janine Bryan and Frank J Taddeo and Shuang Lu and Mark T. Esser and Scott C Vuocolo and Carlos A Sattler and Eliav Barr},
  journal={International journal of cancer},
  year={2008},
  volume={122 6},
  pages={1311-8}
}
The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus-like-particle vaccine has been shown to be 95-100% effective in preventing HPV 6/11/16/18-related cervical and genital disease in women naive to vaccine HPV types. A total of 6,004 female subjects aged 9-24 were recruited from Brazil, Mexico, Colombia, Costa Rica, Guatemala and Peru. Subjects were randomized to immunization with intramuscular… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

HPV in the etiology of human cancer

  • N Munoz, X Castellsague, AB de Gonzalez, L. Gissman
  • Vaccine
  • 2006
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…